Contemporary benefit-harm profile over two decades in primary prophylactic ICD-therapy
- PMID: 31317573
- PMCID: PMC6788478
- DOI: 10.1002/clc.23234
Contemporary benefit-harm profile over two decades in primary prophylactic ICD-therapy
Abstract
Background: Implantable cardioverter defibrillator (ICD) was implemented into clinical routine more than 20 years ago. Since then, ICD therapy became standard therapy for primary and secondary prevention of sudden cardiac death in clinical practice.
Objectives: Aim of the study was to evaluate the benefit-harm profile of contemporary primary prophylactic ICD therapy.
Methods: A total of 1222 consecutive patients of a prospective single-center ICD-registry were analyzed who underwent primary prophylactic ICD implantation between 2000 and 2017. Patients were divided into two groups according to the implantation year: 2010-2017 (group 1, n = 579) and 2000-2009 (group 2, n = 643).
Results: The rate of estimated appropriate ICD therapy after 8 years was 51% in the 2000s and 42% in the 2010s (P < .001). The complication rate changed slightly from 53% to 47% (P = .005). This decline was mainly driven by the reduction of inappropriate ICD shocks (30% vs 14%, P < .001) whereas the rate of ICD shock lead malfunction and device/ lead infection remained unchanged over time. Nonischemic cardiomyopathy was an independent predictor for ICD complications without benefit of ICD therapy (HR 1.37, 95% CI 1.07-1.77).
Conclusion: The ICD therapy rate for ventricular arrhythmias in patients with primary prophylactic ICD implantation is decreasing over the last two decades. Complication rate remains high due to an unchanged rate of ICD shock malfunctions and device infections. Nonischemic cardiomyopathy is an independent predictor for ICD complications without benefit of ICD therapy in primary prophylactic ICD-therapy.
Keywords: ICD complications; ICD shock; defibrillation; implantable cardioverter defibrillator (ICD); primary prophylactic ICD.
© 2019 The Authors. Clinical Cardiology published by Wiley Periodicals, Inc.
Conflict of interest statement
The authors declare no potential conflict of interests.
Figures




Similar articles
-
Usefulness of sleep-disordered breathing to predict occurrence of appropriate and inappropriate implantable-cardioverter defibrillator therapy in patients with implantable cardioverter-defibrillator for primary prevention of sudden cardiac death.Am J Cardiol. 2013 May 1;111(9):1319-23. doi: 10.1016/j.amjcard.2013.01.277. Epub 2013 Feb 11. Am J Cardiol. 2013. PMID: 23411108
-
Intensive recreational athletes in the prospective multinational ICD Sports Safety Registry: Results from the European cohort.Eur J Prev Cardiol. 2019 May;26(7):764-775. doi: 10.1177/2047487319834852. Epub 2019 Feb 27. Eur J Prev Cardiol. 2019. PMID: 30813818
-
Arrhythmic burden among asymptomatic patients with ischemic cardiomyopathy and an implantable cardioverter-defibrillator.Heart Rhythm. 2019 Jun;16(6):813-819. doi: 10.1016/j.hrthm.2019.03.030. Heart Rhythm. 2019. PMID: 31153454
-
Prophylactic use of the implantable cardioverter-defibrillator and its effect on the long-term survival, cardiovascular and sudden cardiac death in nonischemic cardiomyopathy patients-a systematic review and meta-analysis.Heart Fail Rev. 2018 Mar;23(2):181-190. doi: 10.1007/s10741-018-9671-6. Heart Fail Rev. 2018. PMID: 29380177
-
Subcutaneous versus transvenous implantable defibrillator: An updated meta-analysis.Heart Rhythm. 2021 Mar;18(3):382-391. doi: 10.1016/j.hrthm.2020.11.013. Epub 2020 Nov 16. Heart Rhythm. 2021. PMID: 33212250
Cited by
-
Lack of Prognostic Value of T-Wave Alternans for Implantable Cardioverter-Defibrillator Benefit in Primary Prevention.J Am Heart Assoc. 2024 Jun 4;13(11):e032465. doi: 10.1161/JAHA.123.032465. Epub 2024 May 28. J Am Heart Assoc. 2024. PMID: 38804218 Free PMC article.
-
Primary Prevention Implantable Cardiac Defibrillators: A Townsville District Perspective.Front Cardiovasc Med. 2020 Oct 27;7:577248. doi: 10.3389/fcvm.2020.577248. eCollection 2020. Front Cardiovasc Med. 2020. PMID: 33195463 Free PMC article.
-
Implantable Cardioverter-Defibrillator for Primary Prevention in Asia.JACC Asia. 2023 Mar 7;3(3):321-334. doi: 10.1016/j.jacasi.2022.11.014. eCollection 2023 Jun. JACC Asia. 2023. PMID: 37323870 Free PMC article. Review.
References
-
- Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877‐883. - PubMed
-
- Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter‐defibrillator for congestive heart failure. N Engl J Med. 2005;352:225‐237. - PubMed
-
- Maggioni AP, Anker SD, Dahlström U, et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC heart failure long‐term registry. Eur J Heart Fail. 2013;15:1173‐1184. - PubMed
-
- Raatikainen MJ, Arnar DO, Zeppenfeld K, Merino JL, Kuck KH, Hindricks G. Current trends in the use of cardiac implantable electronic devices and interventional electrophysiological procedures in the European Society of Cardiology member countries: 2015 report from the European heart rhythm association. Europace. 2015;17(Suppl 4):iv1‐iv72. - PubMed
-
- Køber L, Thune JJ, Nielsen JC, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375:1221‐1230. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical